Patient characteristics
| N=15 patients | |
| Age (years) | 31 (19–51) |
| Sex (F/M) | 13/2 |
| Disease duration (years) | 9 (2–24) |
| Relapses (n) | 4 (1–6) |
| Before treatment | |
| SLEDAI | 18 (6–29) |
| Urine PCR (mg/mmol) | 107 (11–852) |
| C4 (mg/L) | 79 (21–260) |
| C3 (g/L) | 0.6 (0.3–1.3) |
| C4d (mg/L) | 2.05 (0.98–6.40) |
| Anti-dsDNA (IU/ml) | 144 (18–505) |
| Anti-C1q (U/ml) | 75.1 (25.1–135) |
| After treatment (24 weeks) | |
| SLEDAI | 2 (0–13)* |
| Urine PCR (mg/mmol) | 46 (9–134)* |
| C4 (mg/L) | 151 (39–339)* |
| C3 (g/L) | 1.0 (0.5–1.4)* |
| C4d (mg/L) | 1.25 (0.17–3.62)* |
| Anti-dsDNA (IU/ml) | 56.5 (1–374)* |
| Anti-C1q (U/ml) | 27.6 (9.8–71.3)* |
Depicted are median (range).
*Statistically significant (p<0.05) difference from baseline.
PCR, protein:creatinine ratio; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; dsDNA, double stranded DNA.